TIAA CREF Investment Management’s Moderna MRNA Stock Holding History

TIAA CREF Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$578K	Buy	+28,414	New	+$527K	﹤0.01%	2541

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

TIAA CREF Investment Management's MRNA Position: Q1 2019 in Review

TIAA CREF Investment Management opened a new position in Moderna (MRNA) in Q1 2019: 28,414 shares worth $578K. The stake represents ﹤0.01% of the portfolio and ranks #2541 among its holdings.

106 funds tracked by Wall St. Rank hold MRNA as of Q1 2019.

TIAA CREF Investment Management held 28,414 shares of Moderna worth $578K as of Q1 2019.
Moderna was a new TIAA CREF Investment Management position in Q1 2019.
Moderna made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2541 holding.
106 funds tracked by Wall St. Rank held Moderna as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.